Form 4: Regeneron EVP Joseph LaRosa Reports Stock Sale
SEC Form 4
Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,000 shares of common stock on February 26, 2024.
Summary
- On February 26, 2024, Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,000 shares of common stock at a price of $990 per share.
- Following the transaction, LaRosa directly owns 36,543 shares of Regeneron common stock.
- LaRosa also indirectly owns 3,367 shares through a 2022 GRAT and 355 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock sale by an executive. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of stock sale transaction |
| 02/28/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.